Total Payments
$44,543
2024 Payments
$28,806
Companies
66
Transactions
625
Medicare Patients
9,572
Medicare Billing
$1.5M
Payment Breakdown by Category
Royalty/License$25,090 (56.3%)
Food & Beverage$18,656 (41.9%)
Travel$600.96 (1.3%)
Education$195.99 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Royalty or License | $25,090 | 1 | 56.3% |
| Food and Beverage | $18,656 | 600 | 41.9% |
| Travel and Lodging | $600.96 | 21 | 1.3% |
| Education | $195.99 | 3 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Stryker Corporation | $25,491 | 7 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $2,828 | 87 | $0 (2024) |
| GlaxoSmithKline, LLC. | $2,136 | 100 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,669 | 59 | $0 (2024) |
| Insmed, Inc. | $721.31 | 19 | $0 (2024) |
| Genentech USA, Inc. | $701.15 | 29 | $0 (2024) |
| Mylan Specialty L.P. | $622.91 | 28 | $0 (2024) |
| GENZYME CORPORATION | $593.68 | 20 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $558.87 | 20 | $0 (2024) |
| Boston Scientific Corporation | $546.53 | 5 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $28,806 | 121 | Stryker Corporation ($25,090) |
| 2023 | $3,345 | 108 | AstraZeneca Pharmaceuticals LP ($597.67) |
| 2022 | $2,136 | 69 | Stryker Corporation ($299.37) |
| 2021 | $1,106 | 41 | ENCORE MEDICAL, LP ($445.70) |
| 2020 | $1,070 | 39 | AstraZeneca Pharmaceuticals LP ($251.49) |
| 2019 | $2,784 | 79 | Boehringer Ingelheim Pharmaceuticals, Inc. ($405.91) |
| 2018 | $2,684 | 77 | Flexion Therapeutics, Inc. ($490.91) |
| 2017 | $2,613 | 91 | AstraZeneca Pharmaceuticals LP ($413.56) |
All Payment Transactions
625 individual payment records from CMS Open Payments — Page 1 of 25
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $30.61 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 12/26/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $4.78 | General |
| Category: RESPIRATORY | ||||||
| 12/19/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $4.18 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 12/18/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $25.26 | General |
| Category: Respiratory | ||||||
| 12/17/2024 | Harmony Biosciences Llc | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $43.14 | General |
| Category: Narcoplepsy | ||||||
| 12/16/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $15.60 | General |
| Category: Respiratory | ||||||
| 12/12/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $15.52 | General |
| Category: Inflammation | ||||||
| 12/10/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $24.10 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $29.21 | General |
| Category: RESPIRATORY | ||||||
| 11/25/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $32.69 | General |
| Category: Cardiology | ||||||
| 11/22/2024 | Stryker Corporation | ICONIX (Device) | Royalty or License | Cash or cash equivalent | $25,090.38 | General |
| Category: SPORTS MEDICINE | ||||||
| 11/20/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $38.07 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 11/18/2024 | Philips North America LLC | (AK6) Vest Therapy (Device) | Food and Beverage | Cash or cash equivalent | $22.20 | General |
| Category: Medical Device | ||||||
| 11/07/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $21.25 | General |
| Category: IMMUNOLOGY | ||||||
| 11/06/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $36.38 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/05/2024 | Harmony Biosciences Llc | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $49.09 | General |
| Category: Narcoplepsy | ||||||
| 11/04/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $17.44 | General |
| Category: Cardiovascular | ||||||
| 10/29/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $24.09 | General |
| Category: IMMUNOLOGY | ||||||
| 10/28/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $17.82 | General |
| Category: RESPIRATORY | ||||||
| 10/24/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $27.62 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 10/21/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $23.96 | General |
| Category: Respiratory | ||||||
| 10/14/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $23.34 | General |
| Category: Respiratory | ||||||
| 10/10/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $33.47 | General |
| Category: RESPIRATORY | ||||||
| 10/09/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/09/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $16.60 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 2,301 | 3,257 | $673,362 | $305,760 |
| 2022 | 22 | 2,519 | 3,677 | $824,049 | $367,722 |
| 2021 | 16 | 2,438 | 3,834 | $869,780 | $430,479 |
| 2020 | 19 | 2,314 | 3,557 | $801,062 | $397,846 |
Total Patients
9,572
Total Services
14,325
Medicare Billing
$1.5M
Procedure Codes
85
All Medicare Procedures & Services
85 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 280 | 830 | $307,140 | $144,626 | 47.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 358 | 415 | $90,925 | $41,080 | 45.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 162 | 211 | $56,490 | $29,125 | 51.6% |
| 94375 | Test to measure rate of airflow | Office | 2023 | 411 | 559 | $39,060 | $17,065 | 43.7% |
| 99292 | Critical care, each additional 30 minutes | Facility | 2023 | 102 | 193 | $35,390 | $16,912 | 47.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 75 | 75 | $22,890 | $13,063 | 57.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 85 | 87 | $27,255 | $12,371 | 45.4% |
| 71250 | Ct scan of chest without contrast | Office | 2023 | 192 | 215 | $31,875 | $8,872 | 27.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 55 | 78 | $17,845 | $7,612 | 42.7% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 82 | 85 | $13,695 | $3,838 | 28.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 20 | 20 | $3,200 | $1,883 | 58.9% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 30 | 30 | $2,635 | $1,393 | 52.9% |
| 95806 | Sleep study including heart rate, breathing, airflow, and effort | Office | 2023 | 19 | 19 | $7,765 | $1,355 | 17.5% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Office | 2023 | 30 | 30 | $2,190 | $1,092 | 49.9% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 31 | 31 | $2,932 | $949.04 | 32.4% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 31 | 32 | $1,735 | $882.52 | 50.9% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 69 | 74 | $2,440 | $591.33 | 24.2% |
| 94664 | Evaluation of use of breathing device | Office | 2023 | 42 | 42 | $1,050 | $580.00 | 55.2% |
| 99407 | Smoking and tobacco use intensive counseling, more than 10 minutes | Office | 2023 | 16 | 19 | $760.00 | $541.50 | 71.3% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2023 | 67 | 67 | $2,275 | $529.92 | 23.3% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2023 | 57 | 57 | $1,425 | $521.10 | 36.6% |
| 94618 | Test for exercise-induced lung stress | Facility | 2023 | 27 | 28 | $890.00 | $466.18 | 52.4% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 60 | 60 | $1,500 | $409.26 | 27.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 325 | 977 | $381,030 | $177,182 | 46.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 193 | 260 | $77,340 | $37,834 | 48.9% |
About Dr. Joseph Abboud, M.D
Dr. Joseph Abboud, M.D is a Pulmonary Disease healthcare provider based in Bryn Mawr, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1295757649.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joseph Abboud, M.D has received a total of $44,543 in payments from pharmaceutical and medical device companies, with $28,806 received in 2024. These payments were reported across 625 transactions from 66 companies. The most common payment nature is "Royalty or License" ($25,090).
As a Medicare-enrolled provider, Abboud has provided services to 9,572 Medicare beneficiaries, totaling 14,325 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 85 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Bryn Mawr, PA
- Active Since 07/24/2006
- Last Updated 08/12/2025
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1295757649
Products in Payments
- ICONIX (Device) $25,295
- DUPIXENT (Biological) $978.23
- TRELEGY ELLIPTA (Drug) $793.51
- NUCALA (Biological) $786.22
- OFEV (Drug) $783.89
- FASENRA (Biological) $630.09
- Arikayce (Drug) $575.51
- Zilretta (Drug) $490.91
- BEVESPI AEROSPHERE (Drug) $475.26
- XARELTO (Drug) $446.77
- DJO Surgical AltiVate Anatomic System (Device) $445.70
- TEZSPIRE (Biological) $359.40
- SYMBICORT (Drug) $358.84
- WATCHMAN (Device) $347.54
- WAKIX (Drug) $342.32
- YUPELRI (Drug) $335.97
- BREZTRI (Drug) $304.80
- ANORO (Drug) $274.94
- ACTHAR (Biological) $265.81
- Xolair (Biological) $262.24
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Bryn Mawr
Dr. David Prince, M.d, M.D
Pulmonary Disease — Payments: $14,344
Pulmonary Disease $14,344
Dr. Catherine Riley, M.d, M.D
Pulmonary Disease — Payments: $10,559
Pulmonary Disease $10,559
Dr. Clarke Piatt, M.d, M.D
Pulmonary Disease — Payments: $9,533
Pulmonary Disease $9,533
Dr. Andrew Pitman, M.d, M.D
Pulmonary Disease — Payments: $6,321
Pulmonary Disease $6,321
Michael Post, D.o, D.O
Pulmonary Disease — Payments: $5,027
Pulmonary Disease $5,027
Edward Theurkauf, Md, MD
Pulmonary Disease
Pulmonary Disease